vicagrel
Small moleculeexperimental
Clinical trial activity
8 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Aug 30, 2018 (NCT03599284)
Timeline
Indications
Mechanism of action
- Purinergic receptor P2Y12INHIBITOR
P2RY12 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sc(OC(C)=O)cc2C1- Mol. weight
- 379.87 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2042273 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07067775 | Phase 1 | Aug 5, 2025 | Jiangsu vcare pharmaceutical technology co., LTD, Jinlin University |
| NCT06577519 | Phase 3 | Sep 6, 2024 | Jiangsu vcare pharmaceutical technology co., LTD |
| NCT05651074 | Phase 1 | Nov 14, 2022 | Jiangsu vcare pharmaceutical technology co., LTD |
| NCT05162053 | Phase 1 | Dec 31, 2021 | Jiangsu vcare pharmaceutical technology co., LTD, Jinlin University |
| NCT04919551 | Phase 1 | Aug 24, 2021 | Jiangsu vcare pharmaceutical technology co., LTD, Jinlin University |
| NCT04143750 | Phase 1 | Nov 11, 2019 | Jiangsu vcare pharmaceutical technology co., LTD, Soochow University |
| NCT03942458 | Phase 1 | Apr 3, 2019 | Jiangsu vcare pharmaceutical technology co., LTD |
| NCT03599284 | Phase 2 | Aug 30, 2018 | Jiangsu vcare pharmaceutical technology co., LTD |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu vcare pharmaceutical technology co., LTD | For profit | 8 | 8 | 3 | 2018 |
| Jinlin University | Academic/Hospital | 3 | 0 | 1 | 2021 |
| Soochow University | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1